Osborne Clarke advises Terumo on the acquisition of Quirem Medical

Osborne Clarke in Amsterdam has advised Terumo, a global leader in medical technology based in Tokyo, Japan on the acquisition of Quirem Medical, a Netherlands-based healthcare start-up specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy (SIRT), a treatment for liver tumors.

Under the terms of the agreement, Terumo acquired 80.1% of the shares of Quirem Medical. This is over and above its current share position of 19.9%, making Quirem Medical now a wholly owned subsidiary of Terumo. Terumo will make a one-time, up-front payment with additional payments based on the achievement of future milestones by 2030.

Quirem Medical's Holmium products are currently available in Europe, the Middle East and Africa (EMEA). In the coming years, Terumo intends to launch the Holmium Platform globally as part of the ongoing expansion of its interventional oncology (IO) portfolio.

The Osborne Clarke team was led by Partner Herke van Hulst and included Senior Associate Marie-Louise Weeda, Associate Guusje Cornelissen, Civil-law Notary Cars-Jan van Gool and prospective  Civil-Law Notary Mechteld Flohil, Tax Partner Job van der Pol, Employment Partner Jorgo Tsiris, Senior Associate Coen Barneveld Binkhuysen (commercial/IP) and Associates Marleen Huisman (IP/data protection), Wyke Schilstra (employment) and Aram Hovanesjan (tax).

Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and medical device and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. Recent notable work from the team in Amsterdam includes advising the syndicate of investors in the EUR 32 million Series B financing round of VarmX. and advising iOnctura on the EUR 20.1 Series A financing round and the sale of Breath Therapeutics to Zambon.